ADXS News and Press, Advaxis From 09/25/23

QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 Amerityre Corp (AMTY) is expected to report for quarter end 2023-06-30 BYD Co - Class H (BYDDF) is expected to report for quarter end 2023-06-30 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q1 2024 Ea...

Zovio Inc. (ZVOI) is expected to report for quarter end 2023-06-30 Sierra Grande Minerals Inc Ordinary Shares (SIERD) is expected to report for quarter end 2023-06-30 The Intergroup Corporation (INTG) is expected to report for Q1 2024 Fortescue Metals Group Ltd ADR (FSUGY) is expected...

Blue Water Biotech Inc. (BWV) is expected to report $-0.12 for Q2 2023 Lycos Energy Inc (MAAL) is expected to report for quarter end 2023-06-30 Esports Entertainment Group Inc. (GMBL) is expected to report $-2.92 for Q4 2023 SigmaTron International Inc. (SGMA) is expected to report fo...

2023-08-10 17:19:38 ET Advaxis press release ( OTCQX:ADXS ): Q2 GAAP EPS of -$1.82 beats by $0.37 . On June 30, 2023, the Company’s consolidated cash and cash equivalents position was $7.1 million. Revenue Collaboration revenue was $9 thousand in the three month...

Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...

Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...

Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTIO...

ASCO abstract highlights 50% partial response and 100% disease control rates in evaluable desmoid tumor patients treated with AL102 1.2 mg once daily (the selected Phase 3 dose) Tumor response, volume and T2 signal reduction were observed earlier in the 1.2 mg once daily group, with dee...

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update. “Our immediate priority is to complete enr...